Bromodomain Inhibition Attenuates the Progression and Sensitizes the Chemosensitivity of Osteosarcoma by Repressing GP130/STAT3 Signaling

Osteosarcoma is the most common primary malignant bone tumor, and there are few ideal clinically available drugs. The bromodomain and extraterminal domain (BET) protein is an emerging target for aggressive cancer, but therapies targeting the BET in osteosarcoma have been unsuccessful in clinical tri...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Oncol
Autori principali: Jiang, Yafei, Wang, Gangyang, Mu, Haoran, Ma, Xiaojun, Wang, Zhuoying, Lv, Yu, Zhang, Tao, Xu, Jing, Wang, Jinzeng, Li, Yunqi, Han, Jing, Yang, Mengkai, Wang, Zongyi, Zeng, Ke, Jin, Xinmeng, Xue, Song, Yin, Mingzhu, Sun, Wei, Hua, Yingqi, Cai, Zhengdong
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2021
Soggetti:
Oncology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8219214/
https://ncbi.nlm.nih.gov/pubmed/34168981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.642134
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi